vs
Axil Brands, Inc.（AXIL）与礼来（RNA）财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是Axil Brands, Inc.的1.5倍（$12.5M vs $8.1M），Axil Brands, Inc.净利率更高（8.7% vs -1398.3%，领先1407.0%），礼来同比增速更快（434.0% vs 5.2%），Axil Brands, Inc.自由现金流更多（$906.4K vs $-156.9M），过去两年礼来的营收复合增速更高（138.5% vs 12.1%）
Axil Brands是一家总部位于美国的专业消费电子企业，主营高端听力防护设备、音频增强装置及个性化音频配件，旗下产品涵盖定制耳塞、运动蓝牙耳机等，面向全球普通消费者及专业作业群体销售。
礼来是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，在18个国家设有办事处，产品销往全球约125个国家。公司由美国内战时期联邦军退伍军人、药剂师伊莱·礼来于1876年创立，品牌名即取自创始人姓名。
AXIL vs RNA — 直观对比
营收规模更大
RNA
是对方的1.5倍
$8.1M
营收增速更快
RNA
高出428.8%
5.2%
净利率更高
AXIL
高出1407.0%
-1398.3%
自由现金流更多
AXIL
多$157.8M
$-156.9M
两年增速更快
RNA
近两年复合增速
12.1%
损益表 — Q2 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.1M | $12.5M |
| 净利润 | $704.9K | $-174.4M |
| 毛利率 | 68.1% | — |
| 营业利润率 | 11.1% | -1513.5% |
| 净利率 | 8.7% | -1398.3% |
| 营收同比 | 5.2% | 434.0% |
| 净利润同比 | 11.2% | -117.0% |
| 每股收益（稀释后） | $0.09 | $-1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXILRNA
| Q4 25 | $8.1M | — | ||
| Q3 25 | $6.9M | $12.5M | ||
| Q2 25 | $5.8M | $3.8M | ||
| Q1 25 | $6.9M | $1.6M | ||
| Q4 24 | $7.7M | $3.0M | ||
| Q3 24 | $5.9M | $2.3M | ||
| Q2 24 | $6.5M | $2.0M | ||
| Q1 24 | $6.5M | $3.5M |
净利润AXILRNA
| Q4 25 | $704.9K | — | ||
| Q3 25 | $334.3K | $-174.4M | ||
| Q2 25 | $-245.6K | $-157.3M | ||
| Q1 25 | $576.7K | $-115.8M | ||
| Q4 24 | $633.7K | $-102.3M | ||
| Q3 24 | $-109.8K | $-80.4M | ||
| Q2 24 | $49.5K | $-70.8M | ||
| Q1 24 | $781.1K | $-68.9M |
毛利率AXILRNA
| Q4 25 | 68.1% | — | ||
| Q3 25 | 67.6% | — | ||
| Q2 25 | 70.0% | — | ||
| Q1 25 | 71.7% | — | ||
| Q4 24 | 71.1% | — | ||
| Q3 24 | 71.0% | — | ||
| Q2 24 | 71.5% | — | ||
| Q1 24 | 71.5% | — |
营业利润率AXILRNA
| Q4 25 | 11.1% | — | ||
| Q3 25 | 6.0% | -1513.5% | ||
| Q2 25 | 0.8% | -4448.7% | ||
| Q1 25 | 8.4% | -8360.9% | ||
| Q4 24 | 8.7% | -4069.6% | ||
| Q3 24 | -2.4% | -4200.9% | ||
| Q2 24 | 2.6% | -4040.4% | ||
| Q1 24 | -1.6% | -2178.6% |
净利率AXILRNA
| Q4 25 | 8.7% | — | ||
| Q3 25 | 4.9% | -1398.3% | ||
| Q2 25 | -4.3% | -4089.3% | ||
| Q1 25 | 8.3% | -7360.0% | ||
| Q4 24 | 8.2% | -3439.5% | ||
| Q3 24 | -1.9% | -3441.7% | ||
| Q2 24 | 0.8% | -3461.8% | ||
| Q1 24 | 12.1% | -1943.4% |
每股收益（稀释后）AXILRNA
| Q4 25 | $0.09 | — | ||
| Q3 25 | $0.04 | $-1.27 | ||
| Q2 25 | $-0.03 | $-1.21 | ||
| Q1 25 | $0.07 | $-0.90 | ||
| Q4 24 | $0.08 | $-0.80 | ||
| Q3 24 | $-0.02 | $-0.65 | ||
| Q2 24 | $0.11 | $-0.65 | ||
| Q1 24 | $0.04 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.0M | $350.2M |
| 总债务越低越好 | $138.3K | — |
| 股东权益账面价值 | $11.1M | $1.9B |
| 总资产 | $16.2M | $2.1B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资AXILRNA
| Q4 25 | $5.0M | — | ||
| Q3 25 | $4.1M | $350.2M | ||
| Q2 25 | $4.8M | $243.9M | ||
| Q1 25 | $4.7M | $254.2M | ||
| Q4 24 | $5.2M | $219.9M | ||
| Q3 24 | $4.1M | $370.2M | ||
| Q2 24 | $3.3M | $575.8M | ||
| Q1 24 | $4.9M | $471.4M |
总债务AXILRNA
| Q4 25 | $138.3K | — | ||
| Q3 25 | $139.2K | — | ||
| Q2 25 | $140.2K | — | ||
| Q1 25 | $141.0K | — | ||
| Q4 24 | $143.3K | — | ||
| Q3 24 | $144.3K | — | ||
| Q2 24 | $146.6K | — | ||
| Q1 24 | — | — |
股东权益AXILRNA
| Q4 25 | $11.1M | — | ||
| Q3 25 | $10.2M | $1.9B | ||
| Q2 25 | $9.7M | $1.2B | ||
| Q1 25 | $9.7M | $1.3B | ||
| Q4 24 | $8.8M | $1.4B | ||
| Q3 24 | $7.9M | $1.5B | ||
| Q2 24 | $7.7M | $1.2B | ||
| Q1 24 | $8.8M | $830.9M |
总资产AXILRNA
| Q4 25 | $16.2M | — | ||
| Q3 25 | $15.4M | $2.1B | ||
| Q2 25 | $12.9M | $1.4B | ||
| Q1 25 | $13.0M | $1.5B | ||
| Q4 24 | $13.7M | $1.6B | ||
| Q3 24 | $11.4M | $1.6B | ||
| Q2 24 | $11.0M | $1.3B | ||
| Q1 24 | $12.7M | $951.5M |
负债/权益比AXILRNA
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $934.8K | $-156.2M |
| 自由现金流经营现金流 - 资本支出 | $906.4K | $-156.9M |
| 自由现金流率自由现金流/营收 | 11.1% | -1257.6% |
| 资本支出强度资本支出/营收 | 0.3% | 5.7% |
| 现金转化率经营现金流/净利润 | 1.33× | — |
| 过去12个月自由现金流最近4个季度 | — | $-592.3M |
8季度趋势，按日历期对齐
经营现金流AXILRNA
| Q4 25 | $934.8K | — | ||
| Q3 25 | $-739.2K | $-156.2M | ||
| Q2 25 | $194.4K | $-199.7M | ||
| Q1 25 | $-169.9K | $-124.8M | ||
| Q4 24 | $1.0M | $-99.9M | ||
| Q3 24 | $897.3K | $-65.6M | ||
| Q2 24 | $-336.6K | $-65.0M | ||
| Q1 24 | $-912.8K | $-70.4M |
自由现金流AXILRNA
| Q4 25 | $906.4K | — | ||
| Q3 25 | $-747.6K | $-156.9M | ||
| Q2 25 | — | $-203.0M | ||
| Q1 25 | $-258.2K | $-128.6M | ||
| Q4 24 | $941.1K | $-103.8M | ||
| Q3 24 | — | $-67.3M | ||
| Q2 24 | $-394.9K | $-65.5M | ||
| Q1 24 | $-922.1K | $-71.3M |
自由现金流率AXILRNA
| Q4 25 | 11.1% | — | ||
| Q3 25 | -10.9% | -1257.6% | ||
| Q2 25 | — | -5277.1% | ||
| Q1 25 | -3.7% | -8174.3% | ||
| Q4 24 | 12.2% | -3491.0% | ||
| Q3 24 | — | -2881.8% | ||
| Q2 24 | -6.1% | -3204.6% | ||
| Q1 24 | -14.3% | -2012.3% |
资本支出强度AXILRNA
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | 5.7% | ||
| Q2 25 | — | 86.9% | ||
| Q1 25 | 1.3% | 238.6% | ||
| Q4 24 | 0.9% | 131.7% | ||
| Q3 24 | — | 72.9% | ||
| Q2 24 | 0.9% | 26.0% | ||
| Q1 24 | 0.1% | 25.8% |
现金转化率AXILRNA
| Q4 25 | 1.33× | — | ||
| Q3 25 | -2.21× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.29× | — | ||
| Q4 24 | 1.59× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.80× | — | ||
| Q1 24 | -1.17× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
RNA
暂无分部数据
